The FDA approves Axiron, Eli Lilly's (NYSE:LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (OTCPK:ARUXF), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading.
The FDA approves Axiron, Eli Lilly's (NYSE:LLY) topical solution for testosterone replacement...
Recommended For You
More Trending News
About LLY Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| LLY | - | - |
| Eli Lilly and Company | ||